表紙
市場調査レポート

NPS Pharmaceuticals, Inc.の製品パイプライン分析

NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 240934
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
NPS Pharmaceuticals, Inc.の製品パイプライン分析 NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日: 2014年05月30日 ページ情報: 英文 42 Pages
概要

当レポートでは、NPS Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

NPS Pharmaceuticals, Inc.の基本情報

NPS Pharmaceuticals, Inc.の概要

  • 主要情報
  • 企業情報

NPS Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

NPS Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

NPS Pharmaceuticals, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

NPS Pharmaceuticals, Inc.:薬剤プロファイル

  • シナカルセト塩酸塩
  • 組換ヒト副甲状腺ホルモン
  • teduglutide
  • NPSP-790
  • NPSP-795

NPS Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

NPS Pharmaceuticals, Inc.:最近のパイプライン動向

NPS Pharmaceuticals, Inc.:休止中のプロジェクト

NPS Pharmaceuticals, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
  • ALX-0646
  • isovaleramide

NPS Pharmaceuticals, Inc.:企業発表

NPS Pharmaceuticals, Inc.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC04885CDB

Global Markets Direct's, 'NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the NPS Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NPS Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of NPS Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of NPS Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the NPS Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate NPS Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of NPS Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the NPS Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of NPS Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of NPS Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of NPS Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • NPS Pharmaceuticals, Inc. Snapshot
    • NPS Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • NPS Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • NPS Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • NPS Pharmaceuticals, Inc. - Pipeline Products Glance
    • NPS Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • NPS Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • NPS Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • NPS Pharmaceuticals, Inc. - Drug Profiles
    • cinacalcet hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human recombinant parathyroid hormone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • teduglutide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPSP-790
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPSP-795
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • NPS Pharmaceuticals, Inc. - Pipeline Analysis
    • NPS Pharmaceuticals, Inc. - Pipeline Products by Target
    • NPS Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • NPS Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • NPS Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • NPS Pharmaceuticals, Inc. - Recent Pipeline Updates
  • NPS Pharmaceuticals, Inc. - Dormant Projects
  • NPS Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ALX-0646
      • isovaleramide
  • NPS Pharmaceuticals, Inc. - Company Statement
  • NPS Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • NPS Pharmaceuticals, Inc., Key Information
  • NPS Pharmaceuticals, Inc., Key Facts
  • NPS Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • NPS Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • NPS Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014
  • NPS Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • NPS Pharmaceuticals, Inc. - Pre-Registration, 2014
  • NPS Pharmaceuticals, Inc. - Phase III, 2014
  • NPS Pharmaceuticals, Inc. - Phase II, 2014
  • NPS Pharmaceuticals, Inc. - Phase I, 2014
  • NPS Pharmaceuticals, Inc. - Preclinical, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • NPS Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • NPS Pharmaceuticals, Inc. - Dormant Developmental Projects,2014
  • NPS Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014
  • NPS Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • NPS Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • NPS Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • NPS Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top